Skip to main content

Table 1 Sensitivity of B lymphoid cell lines to IQS019

From: Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

Cell lines B lymphoid subtypes TP53 statusa IQS019 cytotoxic effect (referred to untreated cells)
1 μM, 48 h 5 μM, 48 h
DOHH-2 FL wt 26% 100%
WSU-NHL FL del/mut 6% 80%
WSU-FSCCL FL wt 26% 77%
SC-1 FL del/mut 4% 43%
JEKO-1 MCL del/mut 21% 75%
MAVER-1 MCL del/mut 15% 70%
UPN-1 MCL del/mut 14% 66%
HBL-2 MCL del/mut 12% 64%
MINO MCL del/mut 19% 64%
GRANTA-519 MCL wt 26% 63%
Z-138 MCL wt 18% 62%
JVM-2 MCL wt 16% 58%
REC-1 MCL wt 12% 48%
MEC-2 CLL del/mut 12% 51%
JVM-13 CLL wt 7% 46%
MEC-1 CLL wt 9% 33%
SUDHL-16 GCB-DLBCL del/mut 15% 47%
OCI-LY8 GCB-DLBCL del/mut 2% 29%
SUDHL-8 GCB-DLBCL del/mut 15% 32%
OCI-LY10 ABC-DLBCL wt 3% 47%
U-2932 ABC-DLBCL del/mut 15% 51%
  1. a17p13 deletion was assessed by fluorescence in situ hybridization and TP53 mutational status was analyzed by direct sequencing
  2. Abbreviations: FL follicular lymphoma MCL mantle cell lymphoma, CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma